Corbus Pharmaceuticals Holdings (CRBP) Depreciation & Amortization (CF) (2014 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) recorded quarterly Depreciation & Amortization (CF) of $50000.0 in Q3 2025, down 5.66% quarter-over-quarter from $53000.0 in Q2 2025, and down 67.11% on a YoY basis from $152000.0 in Q3 2024.
Corbus Pharmaceuticals Holdings (CRBP) Depreciation & Amortization (CF) (2014 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Depreciation & Amortization (CF) history runs 12 years deep, the most recent figure standing at $50000.0 for Q3 2025.
- In Q3 2025, Depreciation & Amortization (CF) fell 67.11% year-over-year to $50000.0; the TTM figure through Dec 2025 stood at $184000.0 (down 68.71% YoY), while the FY2024 annual figure was $588000.0, down 8.27% from the prior year.
- Depreciation & Amortization (CF) was $50000.0 for Q3 2025 at Corbus Pharmaceuticals Holdings, down from $53000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $272186.0 in Q1 2021 to a low of $50000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $167148.0 across 5 years, with a median of $158130.0 in 2023.
- The sharpest annual moves came in 2021 and 2025: Depreciation & Amortization (CF) increased 26.82% in 2021, then sank 67.11% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $207685.0 in 2021, then declined by 11.21% to $184397.0 in 2022, then fell by 19.74% to $148000.0 in 2023, then slipped by 9.46% to $134000.0 in 2024, then sank by 62.69% to $50000.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $50000.0 (Q3 2025), $53000.0 (Q2 2025), and $81000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 429,663.65 |
| 10 | Corbus Pharmaceuticals Holdings | 133.67 Mn | 105.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Jun 30, 2025 | 53,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Dec 31, 2024 | 134,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Sep 30, 2024 | 152,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Jun 30, 2024 | 150,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Dec 31, 2023 | 148,000.00 |
| Sep 30, 2023 | 153,000.00 |
| Sep 30, 2023 | 153,000.00 |
| Jun 30, 2023 | 158,130.00 |
| Jun 30, 2023 | 158,130.00 |